Drugs / Erwinia Chrysanthemi asparaginase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02647190 | Jan 2016 → Jun 2017 | acute lymphoblastic leukemia | Memorial Sloan Kettering Cancer Center | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Erwinia Chrysanthemi asparaginase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02647190 ↗ |
| Route | Intravenous | “25,000 IU/m2 IV three times a week” NCT02647190 ↗ |